Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China
Aim: Diabetic macular edema (DME) is one of the leading causes of vision impairment in diabetic patients. The aim of this study was to evaluate the cost-effectiveness of faricimab (Vabysmo R ), the first bispecific antibody targeting VEGF-A and ANG-2, for treating DME in China. Materials & method...
Збережено в:
| Автори: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Becaris Publishing Limited
2026-03-01
|
| Серія: | Journal of Comparative Effectiveness Research |
| Предмети: | |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|